Gilead Sciences, Inc.

NasdaqGS:GILD Stock Report

Market Cap: US$155.9b

Gilead Sciences Management

Management criteria checks 3/4

Gilead Sciences' CEO is Dan O'Day, appointed in Mar 2019, has a tenure of 6.75 years. total yearly compensation is $23.69M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 0.046% of the company’s shares, worth $72.47M. The average tenure of the management team and the board of directors is 5.6 years and 7.6 years respectively.

Key information

Dan O'Day

Chief executive officer

US$23.7m

Total compensation

CEO salary percentage7.48%
CEO tenure6.8yrs
CEO ownership0.05%
Management average tenure5.6yrs
Board average tenure7.6yrs

Recent management updates

Recent updates

Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength

Nov 20

Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?

Jul 27
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?

Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are

May 15
Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are

Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance

Apr 25

Revenues Working Against Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price

Apr 15
Revenues Working Against Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price

New HIV, Livdelzi And CAR T Options Will Expand Reach

Gilead's innovation in HIV and oncology treatments supports revenue growth and market expansion in these therapeutic areas.

Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally

Mar 16

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Mar 12
Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Why Gilead Sciences Remains A Buy After A 40% Rally

Feb 27

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Feb 18
Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Gilead Sciences: Diversification Strategy Not Derisked Enough Yet

Feb 11

Gilead Sciences (NASDAQ:GILD) Could Easily Take On More Debt

Feb 09
Gilead Sciences (NASDAQ:GILD) Could Easily Take On More Debt

Gilead: Strong Sales Growth Remains With Veklury And Beyond

Feb 03

Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise

Dec 29

Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure

Dec 18

CEO Compensation Analysis

How has Dan O'Day's remuneration changed compared to Gilead Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

US$8b

Jun 30 2025n/an/a

US$6b

Mar 31 2025n/an/a

US$6b

Dec 31 2024US$24mUS$2m

US$480m

Sep 30 2024n/an/a

US$126m

Jun 30 2024n/an/a

US$1b

Mar 31 2024n/an/a

US$485m

Dec 31 2023US$23mUS$2m

US$6b

Sep 30 2023n/an/a

US$6b

Jun 30 2023n/an/a

US$5b

Mar 31 2023n/an/a

US$6b

Dec 31 2022US$22mUS$2m

US$5b

Sep 30 2022n/an/a

US$3b

Jun 30 2022n/an/a

US$4b

Mar 31 2022n/an/a

US$5b

Dec 31 2021US$19mUS$2m

US$6b

Sep 30 2021n/an/a

US$7b

Jun 30 2021n/an/a

US$5b

Mar 31 2021n/an/a

US$301m

Dec 31 2020US$19mUS$2m

US$123m

Sep 30 2020n/an/a

US$1b

Jun 30 2020n/an/a

-US$257m

Mar 31 2020n/an/a

US$5b

Dec 31 2019US$29mUS$1m

US$5b

Compensation vs Market: Dan's total compensation ($USD23.69M) is above average for companies of similar size in the US market ($USD13.36M).

Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.

CEO

Dan O'Day (60 yo)

6.8yrs
Tenure
US$23,689,392
Compensation

Mr. Daniel P. O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galapagos...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel P. O'Day
Chairman & CEO6.8yrsUS$23.69m0.046%
$ 72.5m
Andrew Dickinson
Chief Financial Officer6.1yrsUS$8.11m0.012%
$ 19.3m
Johanna Mercier
Chief Commercial Officer6.4yrsUS$8.61m0.0086%
$ 13.3m
Erin Burkhart
SVP, Controller & Principal Accounting Officerless than a yearno datano data
Jacquie Ross
Senior Vice President of Treasury and Investor Relations4.9yrsno datano data
Keeley Wettan
Executive VP and General Counsel of Legal & Complianceno datano datano data
Jyoti Mehra
Executive Vice President of Human Resources6.3yrsno datano data
Linda Higgins
Senior Vice President of Research5.8yrsno datano data
Flavius Martin
Executive Vice President of Research4.7yrsno datano data
Janet Dorling
Senior Vice President of Intercontinental Region & Global Patient Solutions5.6yrsno datano data
Bernard Fine
VP of Oncology & Franchise Head of Early Developmentno datano datano data
Stacey Ma
Executive VP of Pharmaceutical Development & Manufacturing3.4yrsno datano data
5.6yrs
Average Tenure
54.5yo
Average Age

Experienced Management: GILD's management team is seasoned and experienced (5.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel P. O'Day
Chairman & CEO6.8yrsUS$23.69m0.046%
$ 72.5m
Anthony Welters
Lead Independent Director5.2yrsUS$474.26k0.00095%
$ 1.5m
Paul Berg
Member of Scientific Advisory Boardno dataUS$16.00kno data
Jacqueline Barton
Independent Director7.9yrsUS$429.96k0.0021%
$ 3.3m
Eugene Schiff
Member of the Scientific Advisory Boardno datano datano data
Robert Schooley
Member of the Scientific Advisory Boardno datano datano data
Harish Manwani
Independent Director7.6yrsUS$424.71k0.0011%
$ 1.8m
John Mellors
Member of the Scientific Advisory Boardno datano datano data
Francis Chisari
Member of the Scientific Advisory Boardno datano datano data
Paul Klotman
Member of the Scientific Advisory Boardno datano datano data
Kelly Kramer
Independent Director9.3yrsUS$434.96k0.00011%
$ 171.5k
Joel Huff
Chairperson of Scientific Advisory Boardno datano datano data
7.6yrs
Average Tenure
72yo
Average Age

Experienced Board: GILD's board of directors are considered experienced (7.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/24 01:32
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gilead Sciences, Inc. is covered by 67 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Brian SkorneyBaird
James BirchenoughBarclays